Newsletter Tool

Today’s Big News

May 14, 2024

AbbVie inks $2B-plus next-gen neuro deal with Gilgamesh

Novo Nordisk's Hemlibra rival hits goals in phase 3, teeing up blockbuster showdown with Roche

Avenzo, BioAge-backer Sands Capital raises new $555M life sciences fund

ASGCT: Why biopharma must face up to the ethical issues around prenatal gene therapies

Featured

AbbVie inks $2B-plus next-gen neuro deal with Gilgamesh

By Gabrielle Masson

AbbVie has inked a pact with Gilgamesh Pharmaceuticals aimed at developing next-gen therapies for psychiatric disorders.

Novo Nordisk's Hemlibra rival hits goals in phase 3, teeing up blockbuster showdown with Roche

By Nick Paul Taylor

Novo Nordisk is coming for Roche’s Hemlibra. A phase 3 trial of the Danish drugmaker’s challenger to the blockbuster hemophilia drug hit its primary endpoint, clearing the path for a filing for approval around the end of the year.

Avenzo, BioAge-backer Sands Capital raises new $555M life sciences fund

By Max Bayer

Sands Capital has raised a $555 million fund, bringing the total amount of committed life science-specific cash to $1.3 billion. The entire firm manages more than $54 billion across public and private bets.

ASGCT: Why biopharma must face up to the ethical issues around prenatal gene therapies

By Helen Floersh

While success for prenatal cell therapies has so far been limited to a handful of case studies, every failure brings the science one step closer to translation. That progress comes with ethical concerns.

Bayer slashed 1,500 roles last quarter as CEO's vision for simpler organization takes shape

By Angus Liu

When Bayer unveiled a restructuring in January, the company didn't provide specifics on the number of planned job cuts. Now, the size of the initial round of cuts shows that CEO Bill Anderson means business.

In new letter to Defense Department, WuXi AppTec refutes claim of secret data transfer

By Angus Liu

Facing potential sanctions from the Department of Defense and a recent allegation that it had transferred a U.S. client's data to Beijing without consent, WuXi AppTec is again rebutting claims of its ties with Chinese authorities.

Guardant Health preps for FDA advisory panel review of its blood-based colorectal cancer screening test

By Conor Hale

The agency has scheduled an advisory panel meeting May 23 to help evaluate the company’s Shield test, which is seeking an in vitro diagnostic approval for screening people ages 45 and up.

Fierce podcasts

Don’t miss an episode

Fulfilling the promise of cell & gene therapies through manufacturing (Part I)

This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing.

Overcoming veteran healthcare hurdles

A closer look at 2023's top biopharma deals and what lies ahead

Resources

Whitepaper

Comprehensive Cell Solutions: Focus on Cellular Therapy Collections

Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis.

Sponsored by: Comprehensive Cell Solutions

Whitepaper

In Vitro Antibodies – Next-Gen Science Delivers Optimized Candidates

Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches.

Sponsored by: Specifica, a Q2 Solutions company

Whitepaper

Branded Digital Companions in Biopharma

This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion.

Presented by: Blue Matter, strategic consultants in the life sciences

Whitepaper

Vaccine Development Challenges in Facing Influenza and COVID-19

Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead.

Sponsored by: PPD®️ Laboratory Services

eBook

Designing Patient-Centered Endpoint in Rare Disease Trials

To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time.

Patient Engagement Series

Discover the secrets behind successful patient engagement

Antibody Profiling: Decoding the Humoral Immune System

Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your copy today!

Straight to Market in an Autoinjector

The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download now to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors.

Presented by: Lonza